PhRMA Launches New Suit Over 340B Orphan Drug Rule

Law360, New York (October 9, 2014, 7:07 PM ET) -- Reviving a high-stakes fight, Pharmaceutical Research and Manufacturers of America on Thursday sued the U.S. Department of Health and Human Services in D.C. federal court to prevent regulators from disciplining drugmakers that sometimes withhold discounts on so-called orphan drugs in the 340B program.



PhRMA’s complaint targets an HHS rule that says orphan drugs should be discounted under 340B when they’re not being used for rare diseases. That policy was issued in July and described as an “interpretive rule” that describes the agency’s reading of an Affordable...

To view the full article, register now.